REVIEW
|
doi:10.20944/preprints202305.1239.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Hodgkin lymphoma; non-Hodgkin lymphoma; PD1 / PD-L1 checkpoint inhibitors; tumor mutational burden; predictive biomarkers
Online: 17 May 2023 (10:52:16 CEST)